Update on FDA approval of XIPERE for macular edema associated with uveitis from Bausch + Lomb


Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

Modern Retina™'s David Hutton speaks with Yolande Barnard, vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, on the company's latest FDA approval of XIPERE (triamcinolone acetonide injectable suspension) for the treatment of macular edema associated with uveitis.

XIPERE is the first—and currently only— FDA-approved therapy utilizing suprachoridal administration.

The American Academy of Ophthalmology (AAO) annual meeting was held November 12 to 15 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The event included Subspecialty Days and a virtual component for remote participation.

Related Content: Additional AAO Content | Ophthalmology | Conference Coverage

Recent Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.